Novartis AG (NVSEF)
162.12
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Novartis Enterprise Value : 345.85B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 345.85B |
| November 12, 2026 | 345.85B |
| November 11, 2026 | 345.85B |
| November 10, 2026 | 343.08B |
| November 09, 2026 | 343.68B |
| November 06, 2026 | 343.68B |
| November 05, 2026 | 342.28B |
| November 04, 2026 | 343.21B |
| November 03, 2026 | 339.33B |
| November 02, 2026 | 337.03B |
| October 30, 2026 | 342.51B |
| October 29, 2026 | 342.51B |
| October 28, 2026 | 341.84B |
| October 27, 2026 | 323.19B |
| October 26, 2026 | 323.19B |
| October 23, 2026 | 322.60B |
| October 22, 2026 | 315.75B |
| October 21, 2026 | 315.75B |
| October 20, 2026 | 316.27B |
| October 19, 2026 | 316.27B |
| October 16, 2026 | 311.44B |
| October 15, 2026 | 312.24B |
| October 14, 2026 | 299.92B |
| October 13, 2026 | 299.92B |
| October 12, 2026 | 310.08B |
| Date | Value |
|---|---|
| October 09, 2026 | 304.05B |
| October 08, 2026 | 296.05B |
| October 07, 2026 | 293.16B |
| October 06, 2026 | 293.16B |
| October 05, 2026 | 293.75B |
| October 02, 2026 | 293.12B |
| October 01, 2026 | 305.83B |
| September 30, 2026 | 305.83B |
| September 29, 2026 | 307.04B |
| September 28, 2026 | 308.99B |
| September 25, 2026 | 299.76B |
| September 24, 2026 | 302.59B |
| September 23, 2026 | 295.04B |
| September 22, 2026 | 295.04B |
| September 21, 2026 | 294.80B |
| September 18, 2026 | 286.47B |
| September 17, 2026 | 301.78B |
| September 16, 2026 | 301.78B |
| September 15, 2026 | 301.78B |
| September 14, 2026 | 288.39B |
| September 11, 2026 | 293.91B |
| September 10, 2026 | 294.25B |
| September 09, 2026 | 295.26B |
| September 08, 2026 | 342.40B |
| September 04, 2026 | 342.40B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 3.456M |
| Oculis Holding AG | 224.54M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.196B |
| Revenue (Quarterly) | 14.52B |
| Total Expenses (Quarterly) | 13.32B |
| EPS Diluted (Quarterly) | 0.631 |
| Gross Profit Margin (Quarterly) | 75.40% |
| Profit Margin (Quarterly) | 8.24% |
| Earnings Yield | 3.23% |
| Operating Earnings Yield | 5.43% |
| Normalized Earnings Yield | 4.058 |